OS Therapies Inc Logo

OS Therapies Inc

Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.

OSTX | US

Overview

Corporate Details

ISIN(s):
US68764Y2072
LEI:
Country:
United States of America
Address:
15825 SHADY GROVE ROAD, 20850 ROCKVILLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

OS Therapies Inc. is a clinical-stage immunotherapy company focused on the development and commercialization of treatments for cancer. The company develops therapies designed to activate the patient's immune system to target and kill cancers expressing the HER2 protein. Its lead candidate, OST-HER2, is a cancer vaccine primarily targeting Osteosarcoma, a type of bone cancer with a significant unmet medical need in both pediatric and adult patients. OS Therapies is also planning to expand its therapeutic development into other HER2-expressing solid tumors, including breast, colorectal, esophageal, lung, and ovarian cancers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all OS Therapies Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OS Therapies Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OS Therapies Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY
ARTELO BIOSCIENCES, INC. Logo
Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.
United States of America
ARTL
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden
ACE
Ascendis Pharma A/S Logo
Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.
United States of America
ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.
United States of America
AAPG
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan
4886
Aspire Biopharma Holdings, Inc. Logo
Developing a nano-platform for rapid, sublingual delivery of reformulated medications.
United States of America
ASBP
ASSEMBLY BIOSCIENCES, INC. Logo
Clinical-stage biopharma developing small-molecule antivirals for herpes, HBV, and HDV.
United States of America
ASMB

Talk to a Data Expert

Have a question? We'll get back to you promptly.